Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report

Pre-clinical data [4–6] had prompted evidences
of the crucial role of Bortezomib mediated NF-kB
inhibition for immune regulation, opening the way for its
successful use in steroid refractory cGvHD developing in
myeloma patients relapsing after allotransplant [7–10]. In
these reports Bortezomib was administered twice-weekly
at conventional doses for a median of 6–8 cycles then
stopped. There are limited data regarding the feasibility
of long-term administration of low-dose Bortezomib with
the aim of obtaining persistent inhibition of cGVHD while
preserving anti-myeloma effect.